Currently, targeted therapy with poly ADP‐ribose polymerase (PARP) inhibitors by genetic testing is covered by insurance in Japan, because PARP inhibitors have been shown to be effective in the presence of DDR alterations (especially in breast cancer susceptibility gene 2; BRCA2) in several cancers, including advanced prostate cancer.31, 32. The gene discussed is BRCA2; the disease is prostate cancer.